Chole Timothy 4/A

What Happened

• Chole Timothy, Senior Vice President and Chief Commercial Officer of Rockwell Medical, was granted 85,000 performance-based restricted stock units (PSUs) on 2025-05-20. The grant is reported as an award/derivative transaction (code A) at $0.00 per share (no cash paid at grant).
• These PSUs do not convert into actual shares unless performance and time-based conditions are met; they are not an open-market purchase or sale.

Key Details

• Transaction date: 2025-05-20; reported in an amended Form 4 filed 2026-04-17 (this award was inadvertently omitted from the original Form 4).
• Grant: 85,000 PSUs; reported price: $0.00 (award/derivative).
• Performance terms (footnote): three-year performance period and term; vesting may occur on or after the first anniversary only if the average closing price over any 60 consecutive trading days during the three-year period equals two times the base price. Base price = $2.14, so the hurdle = $4.28.
• Shares owned after the transaction: not specified in this filing.
• Timeliness: This is an amended filing correcting an omission (late reporting).

Context

• These are contingent equity awards (PSUs). They represent potential future insider ownership only if the stock-price hurdle and time-based vesting conditions are satisfied; they do not indicate an immediate purchase or sale.
• Because the filing is amended to include a previously omitted award, the amendment corrects the record but does not by itself imply any trading intent.